BBIO Bridgebio announces FDA Acceptance of NDA for encaleret for adh1 Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 fo
BBIO Bridgebio announces FDA Acceptance of NDA for encaleret for adh1 Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 for encaleret NDA